Acorda shareholders offered stock
Acorda Therapeutics Inc., a biotechnology company in Hawthorne, said the public will have the opportunity to buy up to $150 million worth of stock and debt. Acorda, which is developing a drug to help people with multiple sclerosis walk, said in a filing with the U.S. Securities and Exchange Commission the offering may include up to $1.37 million shares of common stock. That would be 5.7 percent of the companyÃ¢â‚¬â„¢s outstanding shares. The companyÃ¢â‚¬â„¢s shares are listed on the Nasdaq and were trading at $20.35, down 15 cents, just after the stock market opened this morning. The filing lists the selling shareholders as Saints Capital, Cross Atlantic Partners and Vector Fund Management.